SAT0374 ONSET OF AXIAL SPONDYLOARTHRITIS REPERCUSSIONS ON PATIENTS’ SOCIAL AND FAMILY LIFE: RESULTS FROM THE EUROPEAN MAP OF AXIAL SPONDYLOARTHRITIS (EMAS)
Authors: M. Garrido-Cumbrera, V. Navarro-Compán, C. Bundy, R. Mahapatra, S. Makri, S. Sanz-Gómez, L. Christen, C. J. Delgado-Domínguez, D. Poddubnyy
Journal: Annals of the Rheumatic Diseases (2020)

Background: Axial Spondyloarthritis (axSpA) is associated with a high degree of functional limitation in daily life activities. However, few studies have evaluated the social and family burden from the patient’s perspective. Objectives: To describe the impact of axSpA on social and family life since disease onset, and the associated PROs. Methods: Data from 2,846 unselected patients of the European Map of Axial Spondyloarthritis (EMAS) study through an online survey (2017-2018) across 13 European countries were analysed. The impact of axSpA on social and family life were assessed through four PROs: i) Impact on relationships with the spouse, family, friends, neighbours, and work colleagues since disease onset (5 point Likert scale; 1 “much better” – 5 “much worse”; ii) Frequency of social activities including outings to bars/restaurants, cinema/theatre/museums, practising sports, travel/excursions, and intimate relations since disease onset (5 point Likert scale; 1 “much more” – 5 “much less”); iii) Adaptations made to cope with axSpA since disease onset (yes/no question); iv) The degree of functional limitation in 18 daily activities (3 point Likert scale). Self-reported BASDAI (0-10), spinal stiffness (3-12), functional limitation (0-54), and psychological distress (GHQ-12) were analysed using Pearson’s correlation comparing the impact on relationships and frequency of social activities since disease onset. Results: Among 2,846 participants, mean age was 43.9 years, 61.3% were female, 48.1% had a university degree. The greatest impact on relationships (sum of ‘worse’ and ‘much worse’) since disease onset were those with work-colleagues (44.5%), friends (35.6%), and spouse (30.4%). Sport was the activity they reduced the most since disease onset (64.2%), followed by travel/excursions (57.3%) and intimate relationships (56.4%) (Fig. 1). 55.5% had purchased comfortable shoes (N = 2748) and 43.9% had made adaptations to their workplace (N = 2651). For those who reported their level of functional limitation in daily activities, the greatest limitations were in physical exercise (85.5%), cleaning the house (84.4%) and using stairs (79.2%) (Fig. 2). In the correlation analysis, BASDAI, spinal stiffness, functional limitation, GHQ-12 were associated with a worsening in all of relationships and social activities (p &lt; 0.001) (Table 1). Table 1. Pearson’s correlation between social and family life changes and PROs Relationships: 1 much better – 5 much worse BASDAI Spinal Stiffness Functional Limitation GHQ-12 Spouse 0.157* 0.130* 0.167* 0.258* Family 0.162* 0.133* 0.138* 0.206* Friends 0.211* 0.173* 0.180* 0.282* Neighbours 0.210* 0.165* 0.112* 0.229* Work colleagues 0.229* 0.153* 0.213* 0.334* Frequency activities: 1 much more – 5 much less Bars / restaurants 0.261* 0.246* 0.314* 0.316* Cinemas / theatres / museums 0.291* 0.243* 0.299* 0.338* Do sports 0.271* 0.213* 0.240* 0.242* Travel / excursions 0.308* 0.218* 0.307* 0.362* Intimate relations 0.284* 0.254* 0.288* 0.321* *p &lt;0.001 Figure 1. Reported social and family live changes since disease outset Figure 2. Reported level of functional limitation in daily live activities Conclusion: For most participants the onset of axSpA marked the worsening of personal relationships in different areas, as well as the reduction of social, leisure, and entertainment activities. Acknowledgments: Funded by Novartis Pharma AG Disclosure of Interests: Marco Garrido-Cumbrera: None declared, Victoria Navarro-Compán Consultant of: Abbvie, Lilly, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, MSD, Lilly, Novartis, Pfizer, UCB, Christine Bundy Grant/research support from: Has received unrelated honoraria from Abbvie, Celgene, Janssen, Lilly, Novartis, and Pfizer., Raj Mahapatra: None declared, Souzi Makri: None declared, Sergio Sanz-Gómez: None declared, Laura Christen: None declared, Carlos Jesús Delgado-Domínguez: None declared, Denis Poddubnyy Grant/research support from: AbbVie, MSD, Novartis, and Pfizer, Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB